VPT:CC - Lishman Global Places First Order for Ventripoint's VMS+ Technology
(TheNewswire)
Toronto, Ontario – TheNewswire - July 28, 2025 –Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the“ Corporation ” ) , ( TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received thefirst purchase order from Lishman Global Inc. for VMS+ technology tobe used within its echocardiography image platform in the People’sRepublic of China. Lishman will use the technology within six hybridechocardiography systems built to support technology demonstration,clinical validation, and regulatory submission to the China Food andDrug Administration (“CFDA”).
Previously, Lishman’s Chinese subsidiary had received CFDA approval and a Certificate of Production(CoP) from the CFDA in the People’s Republic of China for the VMS+ product used foranalysis of the right ventricle (RV) only of the heart. Through the manufacture and sale of a limited number ofthese systems Lishman was able to develop market insights, validatethe market opportunity, identify and engage with channel partners andbuild market awareness.
With 32,000 hospitals and rapidly aging demographics,China presents one of the largest single-country opportunities forcardiovascular diagnostics. Cardiovascular disease is the leadingcause of hospital admissions, accounting for ~23% of admissions -nearly double the rate in North America - driven by an agingpopulation and high prevalence of hypertension. Echocardiography usageis especially high in China, and is often mandated prior to surgicalprocedures, increasing the demand for high-quality, affordable andaccessible diagnostic imaging.
“We look forward to working with our Chinese partnersto include the newer capabilities of VMS+ into their hybrid echoproduct,” stated Hugh MacNaught, President and CEO. “Expandingfunctionality to all four cardiac chambers will provide greateraccuracy of echo studies for a wider range of cardiopulmonaryindications. Ventripoint’s proprietary AI enhancement toechocardiography is an important tool for healthcare systems globally.It enables the enhancement of the vast installed base ofechocardiography systems to deliver accurate, affordable andaccessible cardiac imaging”
“We are excited to work with Ventripoint to begin thework of integrating VMS+ within our new products, securing CFDAapproval, and building awareness of our new solutions to the Chineseclinical community” stated Paul Gibson, CTO of Lishman.
About Lishman Global.
Lishman Global was establish in 2012 to assistcompanies to safely enter the Chinese Market. Our partnership modelallows foreign companies to navigate the complex network of regulatoryapprovals and multi-level distribution channels common in the Chinesemedical device market.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Corporation.Although the Corporation believes that the expectations andassumptions on which such forward-looking statements and informationare based are reasonable, undue reliance should not be placed on theforward-looking statements and information because the Corporation cangive no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Corporation'smost recent annual management's discussion and analysis that isavailable on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readersare cautioned that the foregoing list of factors is not exhaustive.The forward-looking statements included in this news release areexpressly qualified by this cautionary statement. The forward-lookingstatements and information contained in this news release are made asof the date hereof and the Corporation undertakes no obligation toupdate publicly or revise any forward-looking statements orinformation, whether as a result of new information, future events orotherwise, unless so required by applicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.